IMRT联合不同化疗方案在早期食管鳞癌患者中不良反应及疗效的比较

doi:10.16352/j.issn.1001-6325.2024.07.1018

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (7): 1018-1022.doi: 10.16352/j.issn.1001-6325.2024.07.1018

IMRT联合不同化疗方案在早期食管鳞癌患者中不良反应及疗效的比较

张伟¹, 张振¹, 刘冬¹, 江后洲¹, 梁伟^2*

1.太和县人民医院肿瘤放疗科,安徽阜阳 236000;
2.安徽医科大学第一附属医院肿瘤放疗科, 安徽合肥 230000

收稿日期:2024-02-26 修回日期:2024-05-22 出版日期:2024-07-05 发布日期:2024-06-26
通讯作者: ^*1072653593@qq.com
基金资助:
安徽省科技重大专项(202103a0720011)

Comparison of adverse reactions and effects of IMRT combined with different chemotherapy regimens in patients with early stage esophageal squamous cell carcinoma

ZHANG Wei¹, ZHANG Zhen¹, LIU Dong¹, JIANG Houzhou¹, LIANG Wei^2*

1. Department of Radiotherapy Oncology, Taihe County People's Hospital, Fuyang 236600;
2. Department of Radiotherapy,Anhui Medical University First Affiliated Hospital,Hefei 230000 China

Received:2024-02-26 Revised:2024-05-22 Online:2024-07-05 Published:2024-06-26
Contact: ^*1072653593@qq.com

摘要/Abstract

摘要： 目的探讨多西他赛+顺铂(DP)及顺铂+5-氟尿嘧啶(PF)方案化疗联合调强适形放射治疗(IMRT)在早期食管鳞癌患者中的不良反应、近期疗效和远期效果。方法选取2021年1月至2022年6月安徽省阜阳市太和县人民医院收治的无远处转移食管鳞癌患者96例为研究对象,将96例患者随机分成观察组48例,对照组48例。对照组采用 PF方案加 IMRT,观察组给予DP方案化疗联合IMRT。比较两组患者治疗期间不良反应发生情况,以及近远期治疗效果。结果与对照组比较,放射性食管炎、放射性肺炎、血液毒性、胃肠道反应等不良反应发生率差异无统计学意义。近期疗效中,观察组治疗总有效率较对照组高(83.3% vs. 62.5%,P＜0.05)。远期疗效中,观察组和对照组的总体生存率、1年生存率、3年生存率分别为70.83%和50.00%、79.36%和60.23%、65.10%和35.52%。观察组中位生存时间(34.4个月)较对照组(18.3个月)长(P＜0.05)。结论 DP方案化疗联合IMRT较PF方案联合IMRT,对于无远处转移食管鳞癌患者,毒副作用未见明显增加,能够有效提高近远期治疗效果,改善疾病预后,可在临床上应用推广。

关键词: 食管鳞癌, 远处转移, 不良反应, 近远期效果, 同步放化疗

Abstract: Objective To investigate the adverse reactions, short-term and long-term effects of DP(docetaxel+cisplatin) regimen and PF(cisplatin+5-fluorouracil) regimen combined with intensity modulated radiation therapy(IMRT)in patients with distant metastatic esophageal squamous carcinoma. Methods From January 2021 to June 2022, 96 patients with non-metastatic esophageal squamous carcinoma were randomly divided into 48 cases in Taihe County People′s Hospital of Fuyang City, Anhui province and 48 cases in control group. Which was treated with DP plus IMRT. The observation group was treated with PF plus IMRT. The occurrence of adverse reactions and the effect of both groups were compared. Results Compared with control group, the difference in the incidence of adverse reaction was not significant. The total effective rate was higher in the observation group than in that in control group (83.3% vs 62.5%, P＜0.05). Overall survival, 1-year survival, 3-year survival in observation and in control group were 70.83% vs 50.00%, 79.36% vs 60.23% and 65.10% vs 35.52%. Long-term outcomes were observed and compared. The median survival time was 34.40 months in the observation group and 18.3 months in control group (P＜0.05). Conclusions DP regimen combined with IMRT is more effective than PF regimen combined with IMRT in the treatment of patients with distant metastatic esophageal squamous carcinoma.

Key words: esophageal squamous cell carcinoma, distant metastasis, adverse reaction, short-term and long-term effect, concurrent chemoradiotherapy

中图分类号:

R735.1

张伟, 张振, 刘冬, 江后洲, 梁伟. IMRT联合不同化疗方案在早期食管鳞癌患者中不良反应及疗效的比较[J]. 基础医学与临床, 2024, 44(7): 1018-1022.

ZHANG Wei, ZHANG Zhen, LIU Dong, JIANG Houzhou, LIANG Wei. Comparison of adverse reactions and effects of IMRT combined with different chemotherapy regimens in patients with early stage esophageal squamous cell carcinoma[J]. Basic & Clinical Medicine, 2024, 44(7): 1018-1022.

参考文献

[1]Wang Y,Xiao Q,Zeng B,et al. Tomotherapy as a neoadjuvant treatment for locally advanced esophageal cancer might increase bone marrow toxicity in comparison with intensity-modulated radiotherapy and volumetric-modulated arc therapy[J]. Med Dosim,2020,45:e6-e12.
[2]Post AB,Nguyen BN,Logan W,et al. Hematologic toxicity of single posterior pencil-beam scanning versus IMRT approaches for esophageal cancer[J].2019,:E195-E195.
[3]Zhao J,Zhang L et al.The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinoma[J].Ann Transl Med,2020:1160-1160.
[4]Gao L,Wang X, et al. A multicenter prospective phase Ⅲ clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concur-rent chemotherapy in patients with esophageal cancer:3JECROG P-02 study protocol[J].BMC Cancer,2020,20:901-901.
[5]Moon SH,Suh YG.The role of modern radiotherapy technology in the treatment of esophageal cancer[J].Korean J Surg,2020,53:184-190.
[6]Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45: 228-247.
[7]Lin H,Hobbs BP,Verma V, et al.Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer[J].J Clin Oncol,2020, 38:1569-1579.
[8]周彬,傅辰春,孙新臣,等.老年食管鳞癌患者单纯放疗和同步放化疗的有效性和安全性比较[J].临床肿瘤学杂,2020,25:71-76.
[9]Venkat PS,Shridhar R,Naghavi AO et al.Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer[J].Dis Esophagus,2017,30:1-9.
[10]沈文斌,高红梅,许金蕊,等.肿瘤局部相关因素对N0期食管癌IMRT预后影响[J].中华放射肿瘤学杂志,2020,29:96-101.
[11]Hu Z,Bi G,Sui Q,et al. Analyses of multi-omics differences between patients with high and low PD1 / PDL1 expression in lung squamous cell carcinoma[J]. Int Immunopharmacol,2020,88: 106-110.
[12]Huang C,Huang D, Zhu Y, et al. Comparison of a concurrent fluorouracil-based regimen and a taxane-based regimen combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma[J].transl oncol,2020,13: 100736-100736.

IMRT联合不同化疗方案在早期食管鳞癌患者中不良反应及疗效的比较

Comparison of adverse reactions and effects of IMRT combined with different chemotherapy regimens in patients with early stage esophageal squamous cell carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	刘珍, 王大连, 张婕, 张其星, 王斐. 强光疗不影响高胆红素血症新生儿细胞免疫功能及出院后近期免疫反应[J]. 基础医学与临床, 2024, 44(3): 379-383.
[2]	田晓怡, 刘颖, 姚瑶, 顾秀丽, 李爱华, 郑胡镛, 宋文琪. 儿童急性淋巴细胞白血病ABCB1、ABCC4和SLCO1B1多态性与大剂量MTX血药浓度及不良反应的相关性[J]. 基础医学与临床, 2022, 42(5): 708-713.
[3]	任孟先, 梁伟, 臧刘兵, 魏雪蕊. 不同放疗剂量同步化疗对食管癌疗效及不良反应的比较[J]. 基础医学与临床, 2022, 42(10): 1539-1542.
[4]	汪秀梅, 王康康, 陈晓燕, 罗金键. 二氢丹参酮Ⅰ促进人食管鳞癌细胞系EC9706凋亡[J]. 基础医学与临床, 2020, 40(7): 955-959.
[5]	王聪懿张诚罗骏吴庆琛. 食管鳞癌中Klf17蛋白表达及其对Eca109细胞迁移和侵袭能力的影响[J]. 基础医学与临床, 2015, 35(5): 590-595.
[6]	杨欣艳盛剑秋王昕李爱琴余东亮谢惠上官俊玲汤姗. 早期和较早期食管癌的光动力治疗[J]. 基础医学与临床, 2013, 33(9): 1176-1179.
[7]	张翔;胡江文;袁方良;高冲;成静;钱晓彬;吴莺;高大庆. DNA修复酶HOGG1在食管鳞癌的表达和临床意义[J]. 基础医学与临床, 2011, 31(1): 53-57.
[8]	侯桂琴刘书漫王莉莉贾欣王丽薛乐勋. 雷帕霉素对食管鳞癌细胞裸鼠移植瘤生长及mTOR/4EBP1信号通路的影响[J]. 基础医学与临床, 2010, 30(2): 155-158.